All In Biotech

BLA 761177 · Ascendis Pharma Encocrinology Div A/S

Skytrofa

Lonapegsomatropin-Tcgd · Injection · Recombinant Human Growth Hormone

NovelOrphan

CDER novel approval, Aug 25, 2021: To treat short stature due to inadequate secretion of endogenous growth hormone

Last checked: Nov 20, 2026Latest source record: Jul 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Aug 25, 2021

Approved uses

n/a

Original approval plus efficacy supplements

Registered trials

6

4 Phase 3, 1 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. FDA's summary: To treat short stature due to inadequate secretion of endogenous growth hormone

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No approvals could be loaded from Drugs@FDA just now.

Clinical trials

Interventional ClinicalTrials.gov studies with "Lonapegsomatropin" as an intervention, any sponsor and status, largest first.

All 6 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Skytrofa (Lonapegsomatropin-Tcgd)

2024 spending

$159K

Beneficiaries

n/a

21 claims

Per beneficiary

n/a

$1,802.83 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$158,521

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 10 on PubMed

Sponsor: Ascendis Pharma Encocrinology Div A/S

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.